Glooko Announces FDA 510(k) Clearance for EndoTool IV Cloud

Why It Matters

The clearance enables hospitals to adopt a proven insulin‑dosing tool with faster, more flexible rollout, improving glycemic safety while lowering IT overhead. It also strengthens Glooko’s foothold in the growing digital‑health market for inpatient diabetes management.

Key Takeaways

• First FDA-cleared cloud insulin dosing platform for hospitals
• Enables scalable deployment, reducing on-premise infrastructure needs
• Preserves EndoTool IV algorithm, improving glycemic safety and efficiency
• Commercial launch slated for U.S. before end of 2026

Pulse Analysis

Hospitals have long wrestled with the complexity of intravenous insulin therapy, balancing tight glycemic targets against the risk of hypoglycemia. Traditional on‑premise decision‑support systems require significant IT resources and periodic updates, limiting rapid adoption across health systems. By moving EndoTool IV to a cloud architecture, Glooko eliminates many of these barriers, allowing clinicians to access patient‑specific dosing recommendations via a secure, centrally managed platform. This shift reflects a broader trend in digital health toward SaaS models that prioritize scalability and continuous improvement.

The FDA’s 510(k) clearance validates EndoTool IV Cloud’s safety and efficacy, giving hospitals confidence to transition from legacy hardware to a cloud‑native solution. The platform retains the same clinically validated algorithm that has demonstrated reduced hypoglycemia episodes and faster time‑to‑target glucose levels. Moreover, centralized updates mean that new clinical guidelines or algorithm refinements can be deployed instantly, ensuring that every bedside benefits from the latest evidence without costly onsite upgrades. For health systems, this translates into lower total cost of ownership and a more consistent standard of care across multiple facilities.

Strategically, the clearance bolsters Glooko’s ambition to become the premier connected‑care partner across both inpatient and outpatient diabetes management. Following its 2025 acquisition of Monarch Medical Technologies, the company is leveraging the EndoTool brand to expand its portfolio beyond remote patient monitoring into critical care environments. As hospitals increasingly seek cloud‑based, interoperable solutions to meet value‑based care metrics, Glooko’s EndoTool IV Cloud positions it to capture a sizable share of the growing market for digital insulin dosing tools, potentially spurring further innovation and competition in the space.